Current version snapshot

Approval reported abroad↗↗Metabolic↗

Current · version 4: Mazdutide↗

Related names recorded in this version: IBI362, LY3305677↗

A June 2025 Suzhou Industrial Park regulator report describes Chinese approval of mazdutide injection for long-term weight management in adults with obesity or overweight. A December 2025 Suzhou government report describes approved diabetes and weight-management indications in China.↗↗

This immutable URL preserves the current public version.
The canonical profile remains the primary reading view. Read the canonical profile.
Update · November 14, 2026

We added a plain-language reader guide with cited answers, published trial results from our human evidence review, ClinicalTrials.gov records naming Innovent and Eli Lilly, and FDA’s current page on unapproved GLP-1 drugs, which names mazdutide. The status line keeps its cited China-only wording. 4523

What this version reported

Large randomized trials in China report weight loss and lower blood sugar. The Chinese approval is reported by local-government sources, not the national approval decision or complete prescribing information. FDA lists mazdutide among unapproved drugs it has warned companies for selling with false research-use labels.↗↗↗↗↗

Organizations named in cited records:
  • West China Hospital↗
  • Innovent Biologics↗
  • U.S. Food and Drug Administration↗

Trial records: NCT07718126

Reader guide in this version

Key takeaway

Mazdutide, also known as IBI362 and LY3305677, is a peptide that activates the receptors for glucagon and GLP-1. It is developed by Innovent Biologics in China and has been studied by Eli Lilly in the United States.5,8,9 Suzhou government reports describe its approval in China in 2025 for long-term weight management and for type 2 diabetes. These are local-government reports, not the national approval decision or full prescribing information.2,3 It is not FDA-approved. FDA says it has warned companies that illegally sold unapproved drugs containing mazdutide falsely labeled as being for research purposes.4 Large randomized trials in China report weight loss and lower blood sugar, with common gastrointestinal side effects.5,6

At a glance

What it is
A glucagon and GLP-1 receptor agonist developed by Innovent Biologics (IBI362) and studied by Eli Lilly (LY3305677).5,8,9
FDA status
Not FDA-approved. FDA lists mazdutide among unapproved drugs it has warned companies for selling with false research-use labels. Suzhou government reports describe approval in China in 2025.2,3,4
Human evidence
Large randomized trials in China in obesity and type 2 diabetes, and a smaller randomized Phase 2 trial in the United States.5,6,7
Evidence strength
Large randomized human trials

What is mazdutide?

Mazdutide is a peptide drug developed in China by Innovent Biologics, which ClinicalTrials.gov lists as the sponsor of trials of IBI362, its development code.5,9

Eli Lilly has sponsored trials of the same drug under the code LY3305677, including a completed Phase 2 trial in the United States.7,8

How is mazdutide thought to work?

Mazdutide is designed to activate the receptors for two hormones, glucagon and GLP-1, which are involved in appetite, blood sugar and energy use.5,7

The sources reviewed here do not establish how much each receptor contributes to the effects reported in trials.5,6

What do human studies show?

In GLORY-1, 610 adults in China with overweight or obesity were randomized to mazdutide or placebo. At week 32, average weight change was −10.09% and −12.55% in the two mazdutide groups and +0.45% with placebo. Gastrointestinal events were common.5

In a 28-week trial of 731 adults in China with type 2 diabetes, HbA1c, a measure of long-term blood sugar, fell 0.24 and 0.30 percentage points more with mazdutide than with dulaglutide, and weight fell more. Gastrointestinal events were more frequent with mazdutide.6

In a Phase 2 trial of 179 adults in the United States, estimated weight change at week 32 ranged from −7.3% to −18.1% across mazdutide groups, compared with −0.9% on placebo; 20% of the highest-exposure group stopped because of adverse events.7

What the evidence base contains

  • Large randomized human trial GLORY-1 (NCT05607680): a randomized, double-blind, placebo-controlled Phase 3 trial in 610 adults in China with overweight or obesity, published in The New England Journal of Medicine.5
  • Large randomized human trial A 28-week randomized Phase 3 trial in 731 adults in China with type 2 diabetes that compared mazdutide with dulaglutide, published in Nature.6
  • Controlled human trial A randomized, placebo-controlled Phase 2 trial in 179 adults in the United States with overweight or obesity.7

Evidence-strength label: Large randomized human trials. How this label is assigned

Is mazdutide approved?

Not by FDA. FDA’s page on unapproved GLP-1 drugs, current as of October 1, 2026, says it has warned companies that illegally sold unapproved drugs containing mazdutide that were falsely labeled for research purposes or not for human consumption.4

A June 27, 2025 report by the Suzhou Industrial Park market regulator describes Chinese approval of mazdutide for long-term weight management in adults with obesity or overweight.2

A December 19, 2025 Suzhou government report describes approved diabetes and weight-management uses in China.3

These are attributable local-government reports, not China’s national approval decision or complete prescribing information. None of the sources reviewed here reports an approval of mazdutide by FDA or in any jurisdiction outside China.2,3,4

Timeline

  1. Results of the GLORY-1 Phase 3 obesity trial are published in The New England Journal of Medicine.5
  2. A Suzhou Industrial Park regulator report describes Chinese approval of mazdutide for long-term weight management.2
  3. A Suzhou government report describes approved diabetes and weight-management uses in China.3
  4. ClinicalTrials.gov lists Eli Lilly’s Phase 2 trial in the United States as completed.8
  5. FDA’s page on unapproved GLP-1 drugs, which names mazdutide, is updated, as shown by its content-current date.4

What is still unknown?

The exact terms of the Chinese approval, which the local-government reports do not set out in full.2,3

Its long-term effects on heart, kidney and liver outcomes: the published trials measured weight and blood sugar over 28 to 32 weeks, and further trials, including in heart failure, are registered.5,6,10

What is in mazdutide products sold outside approved channels, which FDA describes as unapproved.4

Sources for this version

  1. 1
    Pre-hepatectomy Rehabilitation in Living Liver Donors With Mazdutide · record history version 1 · last update posted 2026-07-21 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  2. 2
    June 27, 2025 government report of Chinese approval for mazdutide weight management ↗

    Suzhou Industrial Park Market Supervision Bureau · Official source · Source checked September 15, 2026

  3. 3
    December 19, 2025 government report describing Chinese mazdutide diabetes and weight indications ↗

    Suzhou Municipal Government · Official source · Source checked September 15, 2026

  4. 4
    FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  5. 5
    Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1, 2025) · PMID 40421736 ↗

    The New England Journal of Medicine · Official source · Source checked November 14, 2026

  6. 6
    Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes (2025) · PMID 41407860 ↗

    Nature · Official source · Source checked November 14, 2026

  7. 7
    Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial (2026) · PMID 42628555 ↗

    The Lancet Diabetes & Endocrinology · Official source · Source checked November 14, 2026

  8. 8
    ClinicalTrials.gov record NCT06124807 · retained source version 2026-04-21:5c8024d2506081c76bbe43d846c2785e0fea51ea4fcaad5871b2b0dacb114691 ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  9. 9
    ClinicalTrials.gov record NCT07469800 · retained source version 2026-05-27:81ca4ac5542c9dd986eb9ee84eec93f13dc03f4151273b5eb069ff56c5baf9ac ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  10. 10
    ClinicalTrials.gov record NCT06862908 · retained source version 2026-09-22:928b8a0878066ce68fb99d71bae27f43671911707e3e4a0bbeabad9a2ee02ea0 ↗

    ClinicalTrials.gov · Official source · Source checked November 14, 2026